SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biocontrol Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kurt M. Matis who wrote (2)4/26/1996 11:45:00 PM
From: Peter Rice   of 100
 
Kurt

The Hemoclense treatment does need FDA approval prior to being offerd to the public and is currently undergoing Phase II clinical trials.

Last year, the FDA permitted this treatment to be tested on a small group of AIDS patients. Patients which were beyond all other treatment. Of those treated, 30% saw improvement in the severity of their AIDS symptoms and one under went complete remission. This prompted the FDA to accelerate the testing process to Phase II.

The important thing to remember is that the patients in the first test had almost no immune system left and were very ill. The theory is, if people infected with the AIDS virus are allowed to undergo this treatment while they still have a working immune system and better health, the percentage of those having a positive benefit to the treatment will go up.

On the investment side, Biocontrol has the rights to utilize this process exclusively for AIDS treatment. The interesting thing about the process is that it does not permanently cure the patient or kill the AIDS virus completely. It only reduces the active virus to levels where the body can recover from the effects. The result being that AIDS infected people will need to undergo this process every couple of years. The revenues generated from this process could be substantial as AIDS is a world wide problem.

If this process is successful and gets FDA approval, Biocontrol and its stockholders won't need to worry about the success of the Diasensor.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News